Form 4: Theravance Biopharma SVP Rhonda Farnum Reports Stock Sale
SEC Filing
Rhonda Farnum, SVP at Theravance Biopharma, reports the sale of 4,000 ordinary shares at $9 per share on July 10, 2024, according to a Form 4 filing.
Summary
- Rhonda Farnum, SVP, COMM & MEDICAL AFFAIRS at Theravance Biopharma, Inc., filed a Form 4.
- The filing reports a transaction that occurred on July 10, 2024.
- Farnum sold 4,000 ordinary shares at a price of $9 per share.
- Following the transaction, Farnum beneficially owns 335,965 ordinary shares directly.
- The sale was executed under a pre-arranged 10b5-1 trading plan dated March 14, 2024.
Sentiment
Score: 5
Explanation: The sentiment is neutral as it reports a routine stock sale under a pre-arranged trading plan. It doesn't inherently indicate positive or negative sentiment about the company's prospects.
Industry Context
Form 4 filings are a routine part of the US stock market, providing transparency into the transactions of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.
Stakeholder Impact
- The stock sale by an SVP could be perceived neutrally by shareholders as it was executed under a pre-arranged 10b5-1 trading plan.
Key Dates
| Date | Description |
|---|---|
| 03/14/2024 | Date of the 10b5-1 plan |
| 07/10/2024 | Date of the stock sale transaction |
| 07/12/2024 | Date of signature on the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.